The abstract is read at the publisher; the summary is JClub's.
Targeting peroxynitrite breakdown with FeTPPS prevents development of a trigeminovascular nociceptive phenotype in rats with persistent myogenic TMD comorbid with migraine.
- Why it matters: Persistent myogenic TMD alongside migraine can worsen outcomes and limit treatment response, yet peroxynitrite’s role in this comorbidity is not well defined.
- What they did: Rats received masseteric muscle injection of CFA plus delayed CGRP infusion to model persistent myogenic-TMD comorbid with migraine; electrophysiology and periorbital withdrawal thresholds were used, with 3-nitrotyrosine measured and FeTPPS used to test peroxynitrite involvement.
- The result: Persistent myogenic-TMD exacerbated migraine-relevant neuronal responses to delayed CGRP and increased 3-nitrotyrosine along the trigeminal pain pathway, while FeTPPS prevented the emergence of the hypersensitive, latent-sensitization-like phenotype.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.